P. Pevarello

发表

Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.

A. Isacchi, E. Casale, C. Mercurio, 2010, Journal of medicinal chemistry.

A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitor.

F. Fiorentini, P. Pevarello, M. Brasca, 2006, Bioorganic & medicinal chemistry letters.

Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.

Anna Vulpetti, E. Casale, A. Vulpetti, 2006, Journal of molecular graphics & modelling.

3-Acylaminopyrazole derivatives via a regioselectively N-protected 3-nitropyrazole

G. Traquandi, P. Pevarello, P. Orsini, 2005 .

3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.

Anna Vulpetti, Antonella Isacchi, Enrico Pesenti, 2004, Journal of medicinal chemistry.

Recent drug approvals from the US FDA and EMEA: what the future holds.

P. Pevarello, 2009, Future medicinal chemistry.

Bicyclopyrazoles actifs comme inhibiteurs de la kinase

A. Borgia, T. Bandiera, P. Pevarello, 2007 .

P2X7 antagonists for CNS indications: recent patent disclosures.

P. Pevarello, D. Torino, S. Bovolenta, 2017, Pharmaceutical patent analyst.

Ca(2+) release-activated Ca(2+) channel inhibitors.

P. Pevarello, Chiara Liberati, F. Piscitelli, 2014, Pharmaceutical patent analyst.

Derivatives of kynurenine as inhibitors of rat brain kynurenine aminotransferase

R. Schwarcz, P. Pevarello, M. Varasi, 1996 .

FFA4/GPR120 agonists: a survey of the recent patent literature.

P. Pevarello, C. Kuhn, Chiara Liberati, 2015, Pharmaceutical patent analyst.

PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat.

R. Maj, P. Pevarello, M. Varasi, 1998, European journal of pharmacology.

Anticonvulsant Activity of PNU‐151774E 1 in the Amygdala Kindled Model of Complex Partial Seizures

R. Maj, P. Pevarello, M. Varasi, 1999, Epilepsia.

Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.

J. Oyarzábal, J. Leal, J. Bischoff, 2011, Cancer letters.

Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound.

R. Maj, C. Caccia, P. Pevarello, 1999, The Journal of pharmacology and experimental therapeutics.

4-Phenyl-4-oxo-butanoic acid derivatives inhibitors of kynurenine 3-hydroxylase.

P. Pevarello, M. Varasi, C. Speciale, 1998, Bioorganic & medicinal chemistry letters.

Synthesis of new fenmetazole analogues with potential mixed α2-adrenergic antagonistic activity and noradrenaline-uptake inhibiting properties

P. Pevarello, M. Varasi, P. Dostert, 1991 .

Differentiation between [1,2,4]triazolo[1,5‐a] pyrimidine and [1,2,4]triazolo[4,3‐a]‐ pyrimidine regioisomers by 1H15N HMBC experiments

P. Pevarello, A. Salgado, Carmen Varela, 2010, Magnetic resonance in chemistry : MRC.

3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.

J. Bischoff, C. Mercurio, A. Vulpetti, 2006, Bioorganic & medicinal chemistry letters.

Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water*

M. Sundström, A. Vulpetti, P. Pevarello, 2000, Journal of biomolecular NMR.

Synthesis of [1,2,4]-triazolo[1,5-a]pyrimidines by Dimroth rearrangement of [1,2,4]-triazolo[4,3-a]pyrimidines: A theoretical and NMR study

J. Elguero, P. Pevarello, A. Salgado, 2011 .

Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.

A. Isacchi, E. Casale, C. Mercurio, 2009, Journal of medicinal chemistry.

Benzodipyrazoles: a new class of potent CDK2 inhibitors.

Anna Vulpetti, Alexander Cameron, Roberto D'Alessio, 2005, Bioorganic & medicinal chemistry letters.

3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.

Anna Vulpetti, Enrico Pesenti, Ciro Mercurio, 2005, Journal of medicinal chemistry.

Nitrile oxide cycloaddition of non-activated alkynes: a novel approach to the synthesis of neuroactive isoxazoles

P. Pevarello, R. Amici, M. Varasi, 1993 .

Ion channel blockers for the treatment of neuropathic pain.

S. Francisconi, P. Pevarello, E. Izzo, 2010, Future medicinal chemistry.

Site selectivity in the reactions of 1,3-dipoles and dienes mith tetracyclo [5.3.2.02,10. 03,6]dodeca-4,8,11-Triene

P. Pevarello, R. Gandolfi, M. Burdisso, 1986 .

Interactions of some analogues of the anticonvulsant milacemide with monoamine oxidase.

K. Tipton, P. Pevarello, P. Dostert, 1994, Biochemical pharmacology.

Synthesis and anticonvulsant activity of a new class of 2-[(arylalky)amino]alkanamide derivatives.

P. Pevarello, M. Varasi, P. Dostert, 1998, Journal of medicinal chemistry.

Preclinical evaluation of PNU-151774E as a novel anticonvulsant.

R. Maj, P. Pevarello, M. Varasi, 1998, The Journal of pharmacology and experimental therapeutics.

Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-Kinases*

O. Rabal, J. Oyarzábal, J. Bischoff, 2009, The Journal of Biological Chemistry.

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

A. Isacchi, E. Casale, J. Bischoff, 2010, Bioorganic & medicinal chemistry.

CDK inhibitors in cancer therapy: what is next?

James R Bischoff, M. Barbacid, M. Malumbres, 2008, Trends in pharmacological sciences.

Targeting Cyclin-Dependent Kinases with Small Molecule Inhibitors

J. Bischoff, C. Mercurio, P. Pevarello, 2010 .

6‐Substituted Pyrrolo[3,4‐c]pyrazoles: An Improved Class of CDK2 Inhibitors

C. Mercurio, A. Vulpetti, D. Ballinari, 2007, ChemMedChem.

An analysis of the binding modes of ATP-competitive CDK2 inhibitors as revealed by X-ray structures of protein-inhibitor complexes.

Anna Vulpetti, A. Vulpetti, P. Pevarello, 2005, Current medicinal chemistry. Anti-cancer agents.

Discovery and Development of Safinamide, a New Drug for the Treatment of Parkinson's Disease

P. Pevarello, M. Varasi, 2018 .

Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.

P. Pevarello, Federica Amigoni, Elena Legnaghi, 2012, Pharmaceutical patent analyst.

Cyclin-dependent kinase inhibitors: a survey of the recent patent literature

P. Pevarello, M. Villa, 2005 .

REDUCTIVE ALKYLATION OF a-AMINOAMIDES

P. Pevarello, R. Amici, M. Varasi, 1996 .

NMR-Based screening with competition water-ligand observed via gradient spectroscopy experiments: detection of high-affinity ligands.

Stefan Knapp, Marina Veronesi, Claudio Dalvit, 2002, Journal of medicinal chemistry.

Pyrrolo[3,2-c]quinoline derivatives: a new class of kynurenine-3-hydroxylase inhibitors.

P. Pevarello, M. Varasi, A. della Torre, 1999, Farmaco.

Sodium channel activity and sigma binding of 2-aminopropanamide anticonvulsants.

C. Caccia, P. Pevarello, R. Amici, 1999, Bioorganic & medicinal chemistry letters.

Synthesis and preliminary biological evaluation of new alpha-amino amide anticonvulsants incorporating a dextromethorphan moiety.

R. Maj, C. Caccia, G. Traquandi, 1999, Bioorganic & medicinal chemistry letters.

Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model

P. Pevarello, C. Bendotti, Chiara Liberati, 2021, International journal of molecular sciences.

Pyrazoles as Efficient Adenine-Mimetic Heterocycles for the Discovery of CDK Inhibitors

A. Vulpetti, P. Pevarello, 2006 .

Role of steric, electrostatic and hydrogen bonding effects as face selectivity controlling factors in nitrone cycloadditions

P. Pevarello, R. Gandolfi, A. Rastelli, 1987 .

Structure-Based Approaches to Improve Selectivity: CDK2-GSK3beta Binding Site Analysis

Patrizia Crivori, Anna Vulpetti, Alexander Cameron, 2005, J. Chem. Inf. Model..

3‐Amino‐1,4,5,6‐tetrahydropyrrolo[3,4‐c]pyrazoles: A New Class of CDK2 Inhibitors.

P. Pevarello, 2006 .

Modulation of the kynurine pathway of tryptophan metabolism in search for neuroprotective agents. Focus on kynurenine-3-hydroxylase.

P. Pevarello, M. Varasi, C. Speciale, 2003, Advances in experimental medicine and biology.

Fragment-Hopping-Based Discovery of a Novel Chemical Series of Proto-Oncogene PIM-1 Kinase Inhibitors

Obdulia Rabal, Julen Oyarzabal, Joaquin Pastor, 2012, PloS one.

STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529

J. Bischoff, C. Mercurio, A. Vulpetti, 2005 .

Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man

P. Pevarello, M. Benedetti, R. Battaglia, 1991, European Journal of Drug Metabolism and Pharmacokinetics.

Kinase inhibitors for CNS diseases: an analysis of the recent patent literature.

P. Pevarello, Federica Amigoni, Elena Legnaghi, 2012, Pharmaceutical patent analyst.

Involvement of FAD-dependent polyamine oxidase in the metabolism of milacemide in the rat.

P. Pevarello, M. Strolin Benedetti, P. Dostert, 1992, Xenobiotica; the fate of foreign compounds in biological systems.

Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.

J. Oyarzábal, J. Leal, J. Bischoff, 2011, Cancer letters.

Stereospecificity of 1,3-dipolar cycloadditions of cyclic nitrones to (E) and (Z)-β-nitrostyrenes

P. Pevarello, R. Gandolfi, M. Burdisso, 1987 .